American Journal of Cardiovascular Drugs

, Volume 4, Issue 2, pp 87–106 | Cite as

Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus

  • John A. Colwell
Review Article


Patients with diabetes mellitus (DM) have accelerated atherothrombotic disease of coronary, cerebral, leg, and other vessels. The major cause of death is cardiovascular, and the risk for a myocardial infarction (MI) in a patient with DM who has never had a MI is the same as a nondiabetic individual who has already had one. In this paper, we review the major reasons for a prothrombotic state in patients with DM: alterations in the intrinsic coagulation and fibrinolytic systems and many abnormalities of platelet function. Increased platelet thromboxane production as well as activation of platelet receptors for fibrinogen and or adenosine diphosphate (ADP) are often present, and can be treated with aspirin (acetylsalicylic acid) and/or receptor blockers.

Review of the major primary prevention trials in DM indicates that a significantly reduced risk for MI or major cardiovascular events may be obtained by enteric-coated aspirin, 81–325 mg/day. There is emerging consensus that this is recommended strategy in adult (aged >30 years) patients with DM who are at high vascular risk. Surveys suggest that this includes virtually every patient with type 2 DM in the US, as well as many patients with complicated type 1 DM. These recommendations are also appropriate for secondary prevention.

Data supporting the use of clopidogrel as an alternative drug in the case of aspirin allergy or other contraindications are reviewed. Evidence is presented in support of using aspirin plus clopidogrel in acute coronary syndromes (ACS), and a meta-analysis of six trials of platelet glycoprotein (GP) IIb/IIIa inhibitors and aspirin in diabetic patients with ACS establishes this regimen as an effective choice. Although bleeding episodes are more common with combined antiplatelet therapy for ACS than for aspirin alone, the benefit of a significant reduction in 30-day mortality appears to outweigh the risk of major bleeding.

It is concluded that major advances in our understanding of the prothrombotic state in DM have been made. Evidence from controlled clinical trials supports the use of enteric-coated aspirin, 81–325 mg/day, as a primary and a secondary prevention strategy in adults with DM with high vascular risk. In ACS, combination therapy with aspirin plus clopidogrel or alternatively, aspirin plus a platelet GP IIb/IIIa inhibitor is supported by prospective trial data. These approaches should be added to the other multifactorial preventive strategies directed at lowering the risk for major vascular events in patients with DM.


  1. 1.
    Stamler JM, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44PubMedCrossRefGoogle Scholar
  2. 2.
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291–7PubMedCrossRefGoogle Scholar
  3. 3.
    Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34PubMedCrossRefGoogle Scholar
  4. 4.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRefGoogle Scholar
  5. 5.
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–26PubMedCrossRefGoogle Scholar
  6. 6.
    Colwell JA, Jokl R. Vascular thrombosis in diabetes. In: Porte D, Sherwin R, Rifkin H, editors. Diabetes mellitus: theory and practice. 6th ed. Norwalk (CT): Appleton & Lange, 1996: 207–16Google Scholar
  7. 7.
    Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients: a survey of controlled studies. Haemostasis 1986; 16: 386–416PubMedGoogle Scholar
  8. 8.
    Jokl R, Colwell JA. Clotting disorders in diabetes. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester (UK): John Wiley & Sons Ltd, 1997: 1543–57Google Scholar
  9. 9.
    Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119–25PubMedCrossRefGoogle Scholar
  10. 10.
    Juhan-Vague I, Roui C, Allessi MC, et al. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–62PubMedCrossRefGoogle Scholar
  11. 11.
    Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000; 50: 1–16PubMedCrossRefGoogle Scholar
  12. 12.
    Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199–209PubMedCrossRefGoogle Scholar
  13. 13.
    Ceriello A. Fibrinogen and diabetes mellitus: is it time for intervention trials?. Diabetologia 1997; 33: 731–4CrossRefGoogle Scholar
  14. 14.
    Ceriello A, Giugliano D, Quatraro A, et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33: 163–7PubMedCrossRefGoogle Scholar
  15. 15.
    Gonzalez J, Colwell JA, Sarji KE, et al. Effect of metabolic control with insulin on plasma von Willebrand Factor activity (VIIIR: WF) in diabetes mellitus. Thromb Res 1980; 17: 261–6PubMedCrossRefGoogle Scholar
  16. 16.
    Sarji KE, Schraibman HB, Chambers A, et al. Quantitative studies of von Willebrand factor (vWF in normal and diabetic subjects: role of vWF in second-phase platelet aggregation. Microcirculation 1976; II: 296–7CrossRefGoogle Scholar
  17. 17.
    Kessler L, Wiesel ML, Attali P, et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998; 24: 327–36PubMedGoogle Scholar
  18. 18.
    Winocour PD, Lopes-Virella M, Laimins M, et al. Effect of insulin treatment in streptozotocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen. J Lab Clin Med 1985; 6: 319–25Google Scholar
  19. 19.
    Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989; 3: 370–3Google Scholar
  20. 20.
    Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860–7PubMedCrossRefGoogle Scholar
  21. 21.
    Eriksson P, Reynisdottir S, Lönnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65–71PubMedCrossRefGoogle Scholar
  22. 22.
    Klein RL, Colwell JA. Altered endothelial function in diabetes mellitus: an overview. In: Conn PM, Sowers JR, editors. Contemporary endocrinology: endocrinology of the vasculature. Totowa (NJ): Humana Press Inc, 1996: 125–34CrossRefGoogle Scholar
  23. 23.
    Stiko-Rahm A, Wiman B, Hamsten A, et al. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very-low-density lipoprotein. Arteriosclerosis 1990; 10: 1067–73PubMedCrossRefGoogle Scholar
  24. 24.
    Kooistra T, Bosma PJ, Töns HA, et al. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723–8PubMedGoogle Scholar
  25. 25.
    Jokl R, Laimins M, Klein RL, et al. Platelet plasminogen activator inhibitor 1 in patients with type 2 diabetes. Diabetes Care 1994; 17: 818–23PubMedCrossRefGoogle Scholar
  26. 26.
    Jokl R, Klein RL, Lopes-Virella MF, et al. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type 2 diabetes. Diabetes Care 1995; 18: 1150–5PubMedCrossRefGoogle Scholar
  27. 27.
    Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71–6PubMedGoogle Scholar
  28. 28.
    Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects, a study of two ethnic groups. Diabetes Care 1993; 16: 621–9PubMedCrossRefGoogle Scholar
  29. 29.
    Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 1993; 13: 415–20PubMedCrossRefGoogle Scholar
  30. 30.
    Hornsby WG, Boggess KA, Lyons TJ, et al. Hemostatic alterations with exercise conditioning in NIDDM. Diabetes Care 1990; 13: 87–92PubMedCrossRefGoogle Scholar
  31. 31.
    Fattal PG, Schneider DJ, Sobel BE, et al. Posttranscriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992; 267: 12412–5PubMedGoogle Scholar
  32. 32.
    Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin or expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890–5PubMedCrossRefGoogle Scholar
  33. 33.
    Calles-Escandon J, Mirza SA, Sobel BE, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 290–3PubMedCrossRefGoogle Scholar
  34. 34.
    Sagel J, Colwell JA, Crook L, et al. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975; 82: 733–8PubMedGoogle Scholar
  35. 35.
    Colwell JA, Nair RM, Halushka PV, et al. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979; 28: 394–400PubMedCrossRefGoogle Scholar
  36. 36.
    Colwell JA. Aspirin therapy in diabetes. Diabetes 1997; 20: 1767–71Google Scholar
  37. 37.
    American Diabetes Association. Clinical practice recommendations. Diabetes Care 2002; 24: 562–3Google Scholar
  38. 38.
    Fuster V, Badimon J, Chesebro JH. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996; 26 (4 Suppl.): 269S–84SGoogle Scholar
  39. 39.
    Davies MJ. Stability and instability: two faces of coronary atherosclerosis: The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013–20PubMedCrossRefGoogle Scholar
  40. 40.
    Falk E, Ahah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71PubMedCrossRefGoogle Scholar
  41. 41.
    Halushka PV, Rogers RC, Loadholt CB. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87–96PubMedGoogle Scholar
  42. 42.
    Winocour PD, Lopes-Virella M, Laimins M, et al. Time course of changes in in vitro platelet function and plasma von Willebrand factor activity (VIIIR: WF) and factor VIII-related antigen (VIIIR: Ag) in the diabetic rat. J Lab Clin Med 1983; 102: 795–804PubMedGoogle Scholar
  43. 43.
    Kwaan HC, Colwell JA, Cruz S, et al. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236–46PubMedGoogle Scholar
  44. 44.
    Leet H, Paton RC, Passa P. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res 1981; 24: 143–50PubMedCrossRefGoogle Scholar
  45. 45.
    Van Zile J, Kilpatrick M, Laimins M, et al. Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes 1981; 30: 575–82PubMedCrossRefGoogle Scholar
  46. 46.
    Watanabe J, Wohltmann HJ, Klein RL, et al. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes 1988; 37: 1652–7PubMedCrossRefGoogle Scholar
  47. 47.
    Winocour PD, Watala C, Kinlough-Rathbone RL. Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid ratio in isolated platelet membranes from diabetic and control subjects. Thromb Haemost 1992; 67: 575–81Google Scholar
  48. 48.
    Watala C, Boncer M, Golanski J, et al. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes. Eur J Haematol 1998; 61: 319–26PubMedCrossRefGoogle Scholar
  49. 49.
    Sarji KE, Kleinfelder J, Brewington P, et al. Decreased platelet vitamin C in diabetes mellitus: possible role in hyperaggregation. Thromb Res 1979; 15: 639–50PubMedCrossRefGoogle Scholar
  50. 50.
    Winocour PD, Laimins M, Colwell JA. Platelet survival in streptozotocin-induced diabetic rats. Thromb Haemost 1984; 51: 307–12PubMedGoogle Scholar
  51. 51.
    Davi G, Belvedere M, Vigneri S, et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type 1 in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 76: 34–7PubMedGoogle Scholar
  52. 52.
    Kwaan HC, Colwell JA, Suwanwela N. Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes 1972; 21: 108–13PubMedGoogle Scholar
  53. 53.
    Ishibashi T, Tanaka K, Taniguchi Y. Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats. Diabetes 1981; 30: 601–6PubMedCrossRefGoogle Scholar
  54. 54.
    Sima AAF, Chakrabarti S, Garcia-Salinas R, et al. The BB-rat: an authentic model of human diabetic retinopathy. Curr Eye Res 1985; 4: 1087–92PubMedCrossRefGoogle Scholar
  55. 55.
    Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50: 1432–9PubMedCrossRefGoogle Scholar
  56. 56.
    Trovati M, Anfossi G. Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus. Curr Diab Rep 2002; 2: 316–22PubMedCrossRefGoogle Scholar
  57. 57.
    Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476–85PubMedCrossRefGoogle Scholar
  58. 58.
    Tschoepe D, Driesch E, Schwippert B, et al. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycaemia. Diabetes 1995; 44: 890–4PubMedCrossRefGoogle Scholar
  59. 59.
    Tschoepe D, Rosen P, Schwippert B, et al. Platelets in diabetes: the role in haemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993; 19: 122–8PubMedCrossRefGoogle Scholar
  60. 60.
    Tschoepe D, Rauch R, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997; 29: 631–5PubMedCrossRefGoogle Scholar
  61. 61.
    Tschoepe P, Oresen L, Kaufmann S, et al. Evidence for abnormal glycoprotein receptor expression on diabetic platelets. Eur J Clin Invest 1990; 20: 166–70PubMedCrossRefGoogle Scholar
  62. 62.
    Tschoepe D, Schwippert G, Schettler B, et al. Increased GPIIb/IIIa expression and altered DNA-ploidy pattern in megacaryocytes of diabetic BB rats. Eur J Clin Invest 1992; 22: 591–8CrossRefGoogle Scholar
  63. 63.
    Tschoepe D, Roesen P, Esser J, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433–8PubMedCrossRefGoogle Scholar
  64. 64.
    Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152–60PubMedCrossRefGoogle Scholar
  65. 65.
    Loscalzo J. Nitric oxide insufficiency, platelet activation and arterial thrombosis. Circ Res 2001; 88: 756–62PubMedCrossRefGoogle Scholar
  66. 66.
    Mutus B, Rabini RA, Staffolani R, et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001; 44: 979–82PubMedCrossRefGoogle Scholar
  67. 67.
    Brodsky SV, Morrishow AM, Dharia N, et al. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001; 280: F480–6PubMedGoogle Scholar
  68. 68.
    Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001; 37: 744–53PubMedCrossRefGoogle Scholar
  69. 69.
    Srivastava K, Dash D. Changes in membrane microenvironment and signal transduction in platelets from NIDDM patients: a pilot study. Clin Chim Acta 2002; 317: 213–20PubMedCrossRefGoogle Scholar
  70. 70.
    Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188–95PubMedCrossRefGoogle Scholar
  71. 71.
    Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca2+ homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480–9PubMedGoogle Scholar
  72. 72.
    Fusman R, Rotstein R, Elishkewich K, et al. Image analysis for the detection of increased erythrocyte, leukocyte and platelet adhesiveness/aggregation in the peripheral blood of patients with diabetes mellitus. Acta Diabetol 2001; 38: 129–34PubMedCrossRefGoogle Scholar
  73. 73.
    Kaplar M, Keppelmayer J, Veszpremi A, et al. The possible association of in vivo leukocyte-platelet heterophylic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419–22PubMedCrossRefGoogle Scholar
  74. 74.
    Marcus AJ. Editorial perspective: aspirin as an antithrombotic medication. N Engl J Med 1983; 309: 1515–7PubMedCrossRefGoogle Scholar
  75. 75.
    Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94PubMedCrossRefGoogle Scholar
  76. 76.
    Sattiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–6CrossRefGoogle Scholar
  77. 77.
    Mills DCB, Puri R, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430–6PubMedCrossRefGoogle Scholar
  78. 78.
    Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101–8PubMedCrossRefGoogle Scholar
  79. 79.
    Coutré S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med 1995; 46: 257–65PubMedCrossRefGoogle Scholar
  80. 80.
    Fitzgerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247–57PubMedCrossRefGoogle Scholar
  81. 81.
    Dabaghi SF, Kamat SG, Payne J, et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 1994; 74: 720–3PubMedCrossRefGoogle Scholar
  82. 82.
    DiMinno G, Silver MJ, Cerbone AM, et al. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886–91PubMedGoogle Scholar
  83. 83.
    Clarke RJ, Mayo G, Price P. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41PubMedCrossRefGoogle Scholar
  84. 84.
    Valles J, Santos MT, Anar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–5PubMedCrossRefGoogle Scholar
  85. 85.
    Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–5PubMedCrossRefGoogle Scholar
  86. 86.
    Meade TW, Brennan PJ, on behalf of the MRC General Practice Research Framework. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–7PubMedCrossRefGoogle Scholar
  87. 87.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62PubMedCrossRefGoogle Scholar
  88. 88.
    Stys T, Lawson WE, Smaldone G, et al. Does aspirin attenuate the beneficial effects of angiotensin converting enzyme inhibition in heart failure?. Arch Intern Med 2000; 160: 1409–13PubMedCrossRefGoogle Scholar
  89. 89.
    Leor J, Reichr-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33(7): 1920–5PubMedCrossRefGoogle Scholar
  90. 90.
    Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17PubMedCrossRefGoogle Scholar
  91. 91.
    Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394–405PubMedGoogle Scholar
  92. 92.
    Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800–6PubMedCrossRefGoogle Scholar
  93. 93.
    Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767–71PubMedCrossRefGoogle Scholar
  94. 94.
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989; 321: 129–35CrossRefGoogle Scholar
  95. 95.
    ETDRS Investigators. Aspirin effects on mortality and morbidity in prints with diabetes mellitus. JAMA 1992; 268: 1292–300CrossRefGoogle Scholar
  96. 96.
    Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89–95CrossRefGoogle Scholar
  97. 97.
    TIMAD Study Group. Ticlopidine treatment reduces the progression of non-proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577–83CrossRefGoogle Scholar
  98. 98.
    The Damad Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes 1989; 38: 491–8CrossRefGoogle Scholar
  99. 99.
    Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology 1991; 98: 757–65Google Scholar
  100. 100.
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502CrossRefGoogle Scholar
  101. 101.
    Steinhubl SR, Berger BP, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20PubMedCrossRefGoogle Scholar
  102. 102.
    The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436–43CrossRefGoogle Scholar
  103. 103.
    (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management. N Engl J Med 1998; 338: 1498–505Google Scholar
  104. 104.
    (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med 1998; 338: 1488–97Google Scholar
  105. 105.
    Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab an outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915–24PubMedCrossRefGoogle Scholar
  106. 106.
    The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina: platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation 1998; 97: 2386–95CrossRefGoogle Scholar
  107. 107.
    Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Am Heart J 2000; 139: 563–6PubMedCrossRefGoogle Scholar
  108. 108.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRefGoogle Scholar
  109. 109.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRefGoogle Scholar
  110. 110.
    Colwell JA, Bingham SF, Abraira C, et al. Veterans administration cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene: II. effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9: 140–8PubMedCrossRefGoogle Scholar
  111. 111.
    “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14 (5): 14Google Scholar
  112. 112.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39CrossRefGoogle Scholar
  113. 113.
    Bhatt DL, Marso SP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus. [abstract]. J Am Coll Cardiol 2000; 35 Suppl. A: 409AGoogle Scholar
  114. 114.
    Mangano DT, for the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309–17CrossRefGoogle Scholar
  115. 115.
    AHA Scientific Statement. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 up date. Circulation 2002; 106: 388–91CrossRefGoogle Scholar
  116. 116.
    Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265–71PubMedCrossRefGoogle Scholar
  117. 117.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  118. 118.
    Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24: 197–201PubMedCrossRefGoogle Scholar
  119. 119.
    US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Ann Intern Med 2002; 136(2): 161–72Google Scholar
  120. 120.
    Cull CA, Neil A, Holman RR. Changing aspirin use in UK patients with type 2 diabetes. Diabetes 2002; 51 Suppl. 2: A156Google Scholar
  121. 121.
    Krein SL, Vijan S, Pogach LM, et al. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care 2002; 25: 965–70PubMedCrossRefGoogle Scholar
  122. 122.
    Wood DM, Plehwe WE, Colman PG. Aspirin usage in a large teaching hospital diabetes clinic setting. Diabet Med 1999; 16: 605–8PubMedCrossRefGoogle Scholar
  123. 123.
    Krumholz HM, Chen YT, Want Y, et al. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med 2001; 161: 538–44PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Informotion BV 2004

Authors and Affiliations

  • John A. Colwell
    • 1
  1. 1.Medical University of South CarolinaCharlestonUSA

Personalised recommendations